

# PBP Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP8092a

## Product Information

---

<b>Application</b>	WB, IHC-P, E
<b>Primary Accession</b>	<a href="#">P30086</a>
<b>Other Accession</b>	<a href="#">P48737</a>
<b>Reactivity</b>	Human, Mouse
<b>Predicted</b>	Monkey
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Isotype</b>	Rabbit IgG
<b>Clone Names</b>	RB3718
<b>Calculated MW</b>	21057
<b>Antigen Region</b>	1-30

## Additional Information

---

<b>Gene ID</b>	5037
<b>Other Names</b>	Phosphatidylethanolamine-binding protein 1, PEBP-1, HCNPPp, Neuropolypeptide h3, Prostatic-binding protein, Raf kinase inhibitor protein, RKIP, Hippocampal cholinergic neurostimulating peptide, HCNP, PEBP1, PBP, PEBP
<b>Target/Specificity</b>	This PBP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human PBP.
<b>Dilution</b>	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
<b>Format</b>	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	PBP Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

---

<b>Name</b>	PEBP1
-------------	-------

<b>Synonyms</b>	PBP, PEBP
<b>Function</b>	Binds ATP, opioids and phosphatidylethanolamine. Has lower affinity for phosphatidylinositol and phosphatidylcholine. Serine protease inhibitor which inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase (By similarity). Inhibits the kinase activity of RAF1 by inhibiting its activation and by dissociating the RAF1/MEK complex and acting as a competitive inhibitor of MEK phosphorylation.
<b>Cellular Location</b>	Cytoplasm.


## Background

PBP binds ATP, opioids and phosphatidylethanolamine, exhibiting a lower affinity for phosphatidylinositol and phosphatidylcholine. This serine protease inhibitor inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase. PBP contains hippocampal cholinergic neurostimulating peptide (HCNP), which may be involved in the function of the presynaptic cholinergic neurons of the central nervous system. HCNP increases the production of choline acetyltransferase but not acetylcholinesterase.


## References

Tohdoh, N., et al., Brain Res. Mol. Brain Res. 30(2):381-384 (1995).  
Hori, N., et al., Gene 140(2):293-294 (1994).  
Seddiqi, N., et al., J. Mol. Evol. 39(6):655-660 (1994).  
Moore, C., et al., Brain Res. Mol. Brain Res. 37 (1-2), 74-78 (1996).

## Images




The anti-PBP Pab (Cat. #AP8092a) is used in Western blot to detect PBP in HeLa cell lysate.




Western blot analysis of anti-PBP Pab (RB03718) in Y79 cell line lysates (35ug/lane). PBP(arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human cancer



tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.



Formalin-fixed and paraffin-embedded human hepatocarcinoma tissue reacted with PBP antibody (N-term) (Cat.#AP8092a), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

## Citations

---

- [Hippocampal Cholinergic Neurostimulating Peptide Suppresses Acetylcholine Synthesis in T Lymphocytes.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.